HW Headlines
Home » Archives for January 2023

Month: January 2023

FridayJan 27, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Anticipating ‘Best Year Ever’ in 2023

Lexaria Bioscience recently released its 2023 annual letter from CEO Chris Bunka, providing a strategic update to all stakeholders The letter highlights the key milestones achieved in calendar 2022, outlines expectations for calendar 2023, and indicates why Chris Bunka expects 2023 to be the company’s best year so far 1In calendar 2023, Lexaria expects to attain FDA registration for an investigational new drug (“IND”) program and commence Phase 1(b) clinical study evaluating the safety and tolerability of DehydraTECH(TM)-processed CBD as a treatment for hypertension The company will also be pursuing commercial relationships in 2023 even as its R&D continues to…

Continue Reading

WednesdayJan 25, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Uses Patented DehydraTECH(TM) Technology to Increase Bioavailability to Meet Underserved Medical Needs

Bioavailability measures the amount of a substance that enters the bloodstream, with most oral routes providing lower amounts of the drug due to poor bioavailability Studies on nutrients show that not all the nutrients we ingest actually enter the bloodstream due to inhibiting factors in the digestive tract Lexaria’s patented DehydraTECH(TM) technology helps increase bioavailability for active pharmaceutical ingredients (“APIs”), which has been shown through various animal and human clinical studies Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is using its patented DehydraTECH(TM) technology to improve bioavailability and how active pharmaceutical ingredients (“APIs”) enter the bloodstream…

Continue Reading

WednesdayJan 11, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Adds to its Existing Suite of Global Patents with First Granted Patent in Canada

Lexaria has announced patent #3,093,414, its first patent in Canada, its 28th granted patent worldwide, and the first patent from its sixth patent family This patent joins the ranks of previously issued patents in Australia, India, Japan, and the EU, even as similar patent applications for skin-based delivery of patented DehydraTECH formulations remain pending in many countries In Lexaria’s 2018 study, DehydraTECH-processed CBD demonstrated almost a 1,900% increase in CBD permeability through human skin compared to a control formulation that was devoid of any commercial penetration enhancers This patent inches Lexaria closer to taking advantage of the cosmeceuticals market, projected…

Continue Reading

MondayJan 09, 2023 10:30 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-Processed CBD Can be Administered More Effectively at Lower Levels than Other CBD, Boosting Hope for Hypertension Patients

Lexaria, a global innovator in drug delivery platforms, has developed the patented DehydraTECH(TM) platform technology, which has been shown to increase the bio-absorption of various fat-soluble active molecules and drugs In a recently completed study, Lexaria showed that DehydraTECH-processed CBD had exceptional safety and tolerability profile in addition to resulting in a statistically significant lowering of 24-hour ambulatory blood pressure The company also reported that it had demonstrated superior CBD blood absorption levels in its HYPER-H21-4 study from DehydraTECH-CBD relative to those of published comparators At the lowest (3.38 mg/kg) and highest (4.46 mg/kg) dose levels tested, DehydraTECH-CBD resulted in…

Continue Reading

FridayJan 06, 2023 11:15 am

Flora Growth Corp. (NASDAQ: FLGC) Acquisition of Franchise Global Health Completed, Rapid Jump in Potential for European Cannabis Sales

International cannabis operator Flora Growth Corp. is rapidly expanding its global footprint and Colombia-based international supply chain thanks to strategic acquisitions during the past several months Flora’s most recent acquisition was concluded just before Christmas on finalization of an agreement with multi-national operator Franchise Global Health Inc. that strengthens Flora’s position in Europe Franchise Global Health (“FGH”) serves 1,200 pharmacies in Germany, which the companies regard as the doorway to the rest of Europe, and it also has a footprint in Portugal and Denmark, while Flora Growth has completed exports to Switzerland and the Czech Republic Flora reported a 604…

Continue Reading

WednesdayJan 04, 2023 11:15 am

Dosing Begins in Lexaria Bioscience Corp. (NASDAQ: LEXX) Human Clinical Study, Evaluating DehydraTECH(TM)-Nicotine Against Leading Nicotine Oral Pouch Brands

The 36-person human pharmacokinetic randomized, double-blind, cross-over study NIC-H22-1 will compare its patented DehydraTECH(TM)-nicotine to leading nicotine pouches On! and Zyn The white pouch oral delivery of nicotine is thought to avoid harmful lung outcomes that smokers and vapers experience The global nicotine pouch market was valued at $2.33 billion in 2020 and is expected to reach $21.84 billion by 2027, driven by an increase in the number of consumers seeking alternative forms of nicotine that do not involve lung exposure Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, announced that dosing has commenced for its human…

Continue Reading

HempWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 303.498.7722

HempWire
HempWire

303 S Broadway, Suite 317-HW
Denver, CO 80209
(303) 498-7722

Copyright © . HempWire / 303 S Broadway, Suite 317-HW, Denver, CO 80209 (303) 498-7722 / Disclaimers